TAK-360 for Narcolepsy and Idiopathic Hypersomnia

This trial tests the safety and tolerability of the medication TAK-360 for individuals with certain sleep disorders over an extended period. It specifically targets those with narcolepsy (with or without sudden muscle weakness) and idiopathic hypersomnia, a condition characterized by excessive daytime sleepiness and difficulty waking up. Participants will either continue their previous dose of TAK-360 or begin a new dose if they previously received a placebo. This trial suits those who completed an earlier TAK-360 study and still experience excessive daytime sleepiness. Participants must visit the clinic multiple times throughout the study. As a Phase 2, Phase 3 trial, it evaluates TAK-360's effectiveness in an initial group and represents the final step before FDA approval, offering participants a chance to contribute to advancing treatment options.

Research shows that TAK-360 is under study to ensure its safety for treating conditions like idiopathic hypersomnia (IH) and narcolepsy. In earlier studies, participants generally tolerated TAK-360 well. Most reported side effects were mild to moderate, indicating they were not serious.

TAK-360 is unique because it offers a long-term treatment option for narcolepsy and idiopathic hypersomnia, where existing treatments often focus on short-term symptom management. Unlike traditional stimulants that primarily target wakefulness, TAK-360 is designed to provide sustained relief by potentially addressing underlying sleep-wake cycle disruptions. Researchers are excited about TAK-360 due to its potential to maintain effectiveness over a prolonged period, which could significantly improve quality of life for those affected by these sleep disorders.

Research has shown that TAK-360 might help treat sleep disorders like narcolepsy and idiopathic hypersomnia (IH). Early results suggest that TAK-360 could reduce excessive daytime sleepiness, a main symptom of these conditions. In past studies, patients reported finding it easier to stay awake during the day after taking TAK-360. Although detailed data from these studies is not provided here, these improvements are promising signs of TAK-360's potential. However, ongoing trials, including this one where participants will receive one of the available TAK-360 doses, are needed to confirm these early findings.⁶⁷⁸⁹¹⁰